Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)

COVID-19 Clinical Trial

— LEONARDO  

Official title:

A Randomized, Double-blind, Placebo-controlled, Two Parallel Groups, International Multicenter Trial to Evaluate the Effect of Plerixafor in Acute Respiratory Failure Related to COVID-19.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05411575
• Other study ID #: 4LB-LEO-P
• Status: Withdrawn
• Phase: Phase 2
• Start date: July 19, 2022
• Est. completion date: October 2022

Study information

• Verified date: April 2023
• Source: 4P-Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase IIb study, LEONARDO is a multicenter, randomized, double-blind, placebo- controlled, parallel group study, to assess the therapeutic efficacy and safety of Plerixafor in patients over 18 years of age, - with acute respiratory failure related to COVID-19 and - Recently admitted in ICU or equivalent structure (within 48 hours) for COVID-19 related respiratory failure - without invasive mechanical ventilation and - requiring oxygen support ≥ 5L/min to obtain a transcutaneous O2 saturation > 94% A total of 150 participants, will be randomized in a 2:1 ratio to receive either Plerixafor (n=100) or placebo (n=50) as a continuous IV infusion for 7 days (from D1 to D8) in addition to standard of care (e.g. glucocorticoids...). Safety data will be reviewed by an independent Data and Safety Monitoring Board (DSMB) during the study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2022
• Est. primary completion date: October 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female = 18 years of age,
• Using contraceptive consistent with local regulations regarding the methods of contraception for those participating in clinical studies
• Willing and able to provide written informed consent (or provided by legally acceptable representative if he/she is present and if in line with local regulations),
• Admitted in ICU within 48 hours before randomization for COVID-19 related respiratory failure. (ICU or equivalent medical structure according to country specificities e.g., Acute Respiratory Care Unit, High Dependency Care Unit if they can provide: continuous IV infusion,continuous ECG, respiratory rate, percutaneous oxygen saturation screen monitoring, high flow nasal oxygen)
• Not requiring immediate (within 24-36 hours) invasive mechanical ventilation according to investigator's judgment,
• Confirmed pneumoniae due to SARS-CoV-2, Laboratory-confirmed SARS-CoV-2 infection as determined by RT-PCR (in nasopharynx or throat samples) or other commercial or public health assay in any specimen, performed within 2 weeks prior to randomization,
• Acute respiratory failure requiring oxygen support (= 5L/min) to achieve a transcutaneous oxygen saturation > 94%,
• Estimated glomerular filtration rate (eGFR) > 50 mL/min/1.73m2 by the CKD-EPI (Chronic Kidney Disease - Epidemiology Collaboration) equation.

Exclusion Criteria:

• Pregnancy or breast feeding,
• Anticipated transfer to another hospital, which is not a study site within 72 hours of randomisation,
• Need for Invasive mechanical ventilation at time of inclusion,
• Evidence of uncontrolled bacterial pneumopathy or active infection other than SARS-Cov-2 (laboratory confirmation),
• Primitive pulmonary arterial hypertension,
• Cardio-vascular co-morbidity:
• History of vascular ischemic events (myocardial infarction or stroke) or congestive heart failure or peripheral arterial disease,
• History or current significant cardiac rhythm disorders (e.g., ventricular tachycardia),
• Known medical history of proven symptomatic postural hypotension,
• Known cancer (solid or blood) in the last 5 previous years or previous haematological disorders (malignancies and other chronic conditions) or having received bone marrow transplant,
• Inadequate haematological function defined by:
• Neutrophil count < 1.0 x 109/L,
• Haemoglobin < 9.0 g/dL (90 g/L),
• Platelets < 100 x 109/L,
• Kaliemia < 3.5 mmol/L and/or total Calcemia < 2.2 mmol/L,
• Inadequate hepatic function defined by Aspartate aminotransferase (AST) and/or Alanine Aminotransferase (ALT) > 3 x upper limit of normal (ULN) and/or Total bilirubin > 2 x ULN,
• Patients with known allergy to Plerixafor or its excipients.
• Previous (within 4 weeks) or current participation in another clinical study other than an observational study.
• Patients with auto immune disease treated or not,

Related Conditions & MeSH terms

• Acute Lung Injury
• COVID-19
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Syndrome

Intervention

Drug:
• Plerixafor 20 MG/ML [Mozobil]
Plerixafor (Mozobil®) continuous intravenous infusion for 7 days

Other:
• Placebo
Placebo continuous intravenous infusion for 7 days

Locations

Country	Name	City	State
Bulgaria	Multiprofile Hospital for Active Treatment AD Haskovo	Haskovo
Bulgaria	Multiprofile Hospital For Active Treatment Pazardzhik AD	Pazardzhik
Bulgaria	University Multiprofile Hospital for Active Treatment Sveti Georgi EAD	Plovdiv
Bulgaria	Multiprofile Hospital for Active Treatment Dr Ivan SeliminskiSliven AD	Sliven
Bulgaria	MHAT Sveta Anna Sofia AD	Sofia
Bulgaria	Military Medical Academy Multiprofile Hospital for Active Treatment Sofia	Sofia
Bulgaria	University First Multiprofile Hospital for Active Treatment Sofia St John the Baptist	Sofia
Bulgaria	University Hospital for Active Treatment and Emergency Medicine NI Pirogov EAD	Sofia
Bulgaria	University Multiprofile Hospital for Active Treatment Prof Dr Stoyan Kirkovich AD	Stara Zagora
France	Centre Hospitalier d'Argenteuil	Argenteuil
France	Hôpital Saint André	Bordeaux
France	Centre Hospitalier Départemental de Vendée - Les Oudairies	La Roche-sur-Yon
France	Hôpital Haut-Lévêque	Pessac
France	Hôpital Civil de Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
4Living Biotech

Countries where clinical trial is conducted

Bulgaria,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To demonstrate that Plerixafor is able to reduce the need for invasive mechanical ventilation or death in severe COVID-19 patients admitted in Intensive Care Unit (ICU)	Proportion of patients with need for invasive mechanical ventilation or death between randomization and D28	Day 1- Day 28
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Mortality between randomization and D28	Percentage of death (all-cause mortality)	Day 1-Day 28
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Mortality between randomization and D90	Percentage of death (all-cause mortality)	Day 1-Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Ventilator-free days between randomization and D28	Number of Ventilator-free days	Day 1-Day 28
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Duration of mechanical ventilation between randomization and D90	Duration of invasive mechanical ventilation in survivors	Day 1-Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Length of ICU stay between randomization and D90	Number of ICU stay days	Day 1-Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Respiratory function including FEV1, FVC, PaO2 and Transfer Lung Capacity for carbon monoxide (TLCO), 6-minute walk test	Respiratory function at 3 months (FEV-1, FVC, PaO2, TLCO, 6-minute walk test)	Day 1-Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Clinical improvement	Ordinal Scale for Clinical Improvement (Clinical improvement: 7-point ordinal scale of the WHO Master Protocol (WHO, 2020). 1: not hospitalized up to 7:death)	Day 1, Day 8, Day 14 Day 28, Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Level of consciousness	Level of consciousness (Alert, Voice, Pain, Unresponsive scale)	Day 1-Day 8, Day 14, Day 28, Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on SpO2 status	Measure of SpO2 via pulse oxymetry	Day 1-Day 8, Day 14, Day 28, Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Respiratory/oxygenation status	Measure of Partial pressure of oxygen (PaO2), Partial pressure of carbon dioxide (PaCO2), Bicarbonate (HCO3),	Day 1-Day 8, Day 14, Day 28, Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on CRP, fibrinogen and D-dimers levels	Blood CRP, fibrinogen, D-dimers levels	Day 1, Day 3, Day 8, Day 14, Day 28
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Safety AEs	Incidence of treatment-emergent AEs (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs), incidence of treatment on discontinuation and withdrawals due to TEAEs	up to Day 90
Secondary	To evaluate the efficacy of Plerixafor compared to placebo on Safety/Lab tests	Quantification of White Blood Cells count and differential, Red Blood Cells count, hemoglobin level, Mean Corpuscular Volume, Reticulocyte and Platelet counts . Blood Chemistry (Creatinine, AST, ALT, total bilirubin, Potassium, total Calcium)	up to Day 90